Adaptimmune Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Loss per share

Loss per share

3 Months Ended

Mar. 31, 2025

Note 4 — Loss per share

The following tables reconcile the numerator and denominator in the basic and diluted loss per share computation (in thousands):


	Three months ended
	March 31,
	2025		2024
Numerator for basic and diluted loss per share
Net loss attributable to ordinary shareholders	$	(47,584)	$	(48,503)
Net loss attributable to ordinary shareholders used for basic and diluted loss per share	$	(47,584)	$	(48,503)


	Three months ended
	March 31,
	2025	2024
Denominator for basic and diluted loss per share - Weighted average shares outstanding	1,542,159,622	1,451,241,661

The dilutive effect of 277,952,929 and 249,957,127 stock options outstanding for the three months ended March 31, 2025 and 2024 respectively, have been excluded from the diluted loss per share calculation because they would have an antidilutive effect on the loss per share for the period.